pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ERLEADA
drug
save

ERLEADA

updated 6mo ago
by Janssen Biotech Inc
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval60 co-mentions · 15 sources
  • drugapalutamide60 co-mentions · 15 sources
  • companyJanssen Biotech Inc30 co-mentions · 15 sources
  • tagSmall Molecule30 co-mentions · 15 sources

all catalysts(0)

nothing on the calendar yet

Trials studying ERLEADA

  • phase3A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancercompletedn=503
  • phase1A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancerrecruitingn=355
  • phase1A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Canceractive not recruitingn=19
  • phase2Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Studyterminatedn=8
  • phase2Study of Oral MRT-2359 With Apalutamide in Prostate Cancerrecruitingn=25
  • phase2Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Canceractive not recruitingn=26
  • phase2Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancerrecruitingn=78
  • phase3An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)active not recruitingn=982

News(5)

  • ESMO: J&J exec says RIPTAC readout is ‘best data we’ve ever seen’ for a prostate cancer drug
    A year after paying over $3 billion for Halda Therapeutics, Johnson & Johnson has unveiled the first data from its shiny new RIPTAC pipeline it believes could sustain its leading role in prostate c…
    fiercebiotech · 25d ago
  • Kairos seizes moment to push prostate cancer prospect into earlier setting
    Kairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival data.
    fiercebiotech · 1mo ago
  • J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
    J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
    biopharma_dive · 4mo ago
  • #ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remain
    CHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday. Treatment with t…
    endpoints · 5mo ago
  • GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
    We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
    onclive · 6mo ago
brand
ERLEADA
generic
APALUTAMIDE
Data sources
ClinicalTrials.gov
last refreshed 6h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?